Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M

ELUTIA INC.

Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.
Full year net sales $12.3M; net loss from continuing ops $15.9M; net income $53.4M includes gain on BioEnvelope sale.
Submitted 510(k) for NXT-41 base biologic matrix to FDA; clearance expected H2 2026; full NXT-41x clearance in 1H27.
Closed $88M BioEnvelope sale to Boston Scientific; repaid $26.9M debt; cash $36.4M plus $8M escrow.
Initiated strategic review for SimpliDerm product line to focus on NXT-41x launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.